StockData
NovoCure Ltd logo

NovoCure Ltd (NVCR) stock

NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/3031% below fair value
$11.14−0.16 (-1.42%)

Close on Nov 17, 2026Market cap $1.30BP/E –Yield –

NovoCure total assets

Total assets on the balance sheet at the end of each period.

NovoCure's total assets was $828.71M at Sep 30, 2026. For fiscal 2025 it was $804.33M, down 35.2% from the year before. Over ten years it grew 10.1% a year on average. The highest annual figure on record is $1.24B in fiscal 2024.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$804.33M-35.2%
FY2024Dec 31, 2024$1.24B+8.3%
FY2023Dec 31, 2023$1.15B-3.8%
FY2022Dec 31, 2022$1.19B+4.6%
FY2021Dec 31, 2021$1.14B+8.3%
FY2020Dec 31, 2020$1.05B+119.4%
FY2019Dec 31, 2019$479.45M+41.1%
FY2018Dec 31, 2018$339.79M+28.1%
FY2017Dec 31, 2017$265.30M-5.9%
FY2016Dec 31, 2016$282.08M-8.2%
FY2015Dec 31, 2015$307.34M+160.7%
FY2014Dec 31, 2014$117.88M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$828.71M-39.1%
Q2 FY2026Jun 30, 2026$795.19M-36.2%
Q1 FY2026Mar 31, 2026$787.93M-36.9%
Q4 FY2025Dec 31, 2025$804.33M-35.2%
Q3 FY2025Sep 30, 2025$1.36B+11.4%
Q2 FY2025Jun 30, 2025$1.25B+2.8%
Q1 FY2025Mar 31, 2025$1.25B+11.4%
Q4 FY2024Dec 31, 2024$1.24B+8.3%
Q3 FY2024Sep 30, 2024$1.22B+6.6%
Q2 FY2024Jun 30, 2024$1.21B+4.6%
Q1 FY2024Mar 31, 2024$1.12B-4.5%
Q4 FY2023Dec 31, 2023$1.15B-3.8%
Q3 FY2023Sep 30, 2023$1.15B-2.4%
Q2 FY2023Jun 30, 2023$1.16B-0.3%
Q1 FY2023Mar 31, 2023$1.17B+2.1%
Q4 FY2022Dec 31, 2022$1.19B+4.6%
Q3 FY2022Sep 30, 2022$1.17B+4.8%
Q2 FY2022Jun 30, 2022$1.16B+6.0%
Q1 FY2022Mar 31, 2022$1.15B+7.7%
Q4 FY2021Dec 31, 2021$1.14B+8.3%
Q3 FY2021Sep 30, 2021$1.12B+159.9%
Q2 FY2021Jun 30, 2021$1.10B+107.4%
Q1 FY2021Mar 31, 2021$1.07B+112.5%
Q4 FY2020Dec 31, 2020$1.05B+119.4%
Q3 FY2020Sep 30, 2020$431.05M-2.9%
Q2 FY2020Jun 30, 2020$528.94M+30.2%
Q1 FY2020Mar 31, 2020$502.45M+35.7%
Q4 FY2019Dec 31, 2019$479.45M+41.1%
Q3 FY2019Sep 30, 2019$443.86M+40.7%
Q2 FY2019Jun 30, 2019$406.19M+31.1%
Q1 FY2019Mar 31, 2019$370.26M+22.0%
Q4 FY2018Dec 31, 2018$339.79M+28.1%
Q3 FY2018Sep 30, 2018$315.51M+20.3%
Q2 FY2018Jun 30, 2018$309.88M+20.6%
Q1 FY2018Mar 31, 2018$303.48M+14.7%
Q4 FY2017Dec 31, 2017$265.30M-5.9%
Q3 FY2017Sep 30, 2017$262.28M–
Q2 FY2017Jun 30, 2017$257.04M–
Q1 FY2017Mar 31, 2017$264.63M–
Q4 FY2016Dec 31, 2016$282.08M–

More NovoCure figures

See a number that looks wrong?